Physician profile
Demondes Haynes
NPI 1699716837
$808,735.55
in general payments reported to CMS, 2019-2025
32 companies · $174K in 2025
The $174K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67K · 2020: $33K · 2021: $96K · 2022: $133K · 2023: $140K · 2024: $166K · 2025: $174K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $349K · Consulting Fee: $64K · Travel and Lodging: $57K · Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $348,645.00 |
| Consulting Fee | $63,588.75 |
| Travel and Lodging | $57,362.59 |
| Food and Beverage | $11,136.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $794,399.07 | 2019-2025 | Breztri, Airsupra, Tezspire |
| Actelion Pharmaceuticals US, INC. | $6,632.05 | 2019-2023 | Uptravi |
| Astrazeneca Ab | $2,022.00 | 2021 | |
| Amgen INC. | $1,975.00 | 2022 | |
| Glaxosmithkline, LLC. | $991.11 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Pfizer INC. | $451.37 | 2019-2025 | |
| Abbvie INC. | $443.69 | 2021-2025 | |
| Genzyme Corporation | $224.31 | 2024-2025 | |
| Insmed, INC. | $180.29 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $174.33 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.37 | 2019-2025 | Ofev |
| Abiomed | $120.34 | 2023 | Impella |
| Bayer Healthcare Pharmaceuticals INC. | $102.89 | 2019-2021 | |
| Inari Medical, INC. | $93.23 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| United Therapeutics Corporation | $92.48 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $89.08 | 2019-2025 | Zerbaxa |
| Mallinckrodt Enterprises LLC | $88.44 | 2019 | |
| Astellas Pharma US INC | $85.45 | 2019 | |
| Pulmonx Corporation | $72.04 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Genentech USA, INC. | $61.55 | 2019-2021 | |
| Allergan, INC. | $44.20 | 2019 | |
| Grifols USA, LLC | $41.56 | 2019-2023 | Prolastin-C Liquid |
| Gilead Sciences, INC. | $34.12 | 2019 | |
| Ambu INC. | $33.22 | 2025 | |
| Novartis Pharmaceuticals Corporation | $29.23 | 2019-2020 | |
| Mauna Kea Technologies, INC. | $26.64 | 2024 | |
| La Jolla Pharmaceutical Company | $25.91 | 2019-2020 | |
| Philips North America LLC | $20.65 | 2019 | |
| Janssen Biotech, INC. | $18.55 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $15.13 | 2023 | Dupixent |
| Avanos Medical | $14.14 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Demondes Haynes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.